Recruiting
TAD After Chemotherapy in Locally Advanced Breast Cancer
This is an observational study to validate target axillary dissection (TAD) in locally advanced tumors (cN2 and/or cT4).
ClinicalTrials.gov IDNCT05763641
PhaseNot Applicable
Enrollment162
SponsorHospital Universitari de Bellvitge
Age18 Years
SexALL
Conditions studied
Sentinel Lymph Node, Breast Cancer, Locally Advanced
About this study
This is an observational study to validate target axillary dissection (TAD) in locally advanced tumors (cN2 and/or cT4).
Interventions
- Procedure: Target Axillary Dissection — TAD after neoadjuvant chemotherapy and subsequent axillary lymph node dissection
Primary outcomes
- TAD validation in locally advanced breast cancer (3 years)
Eligibility information
Inclusion Criteria:
* Axillary lymph node metastasis proven by cytology
* Clinical or radiological N2a (at least 4 suspicious lymph nodes on axillary ultrasound at diagnosis)
* Extensive T4 subsidiary to axillary lymphadenectomy according to current clinical criteria
* Neoadjuvant chemotherapy
Exclusion Criteria:
* cN3 verified by imaging tests
* N2 due to internal mammary involvement (N2b).
* Tumors whose surrogate molecular subtype is luminal A.
* Patients undergoing neoadjuvant endocrine therapy
* Patients with local recurrences and metastatic tumors.
Study locations
- Hospital de Bellvitge, L'Hospitalet de Llobregat, Barcelona 08907 Spain
- Hospital Clínico y Provincial de Barcelona, Barcelona, 08036 Spain
Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.
Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-09-27.